Same medicine as Suboxone®, all the benefits of BUNAVAIL

BUNAVAIL utilizes BioErodible MucoAdhesive (BEMA®) technology and its unique backing layer to facilitate the unidirectional flow of medication for efficient delivery of buprenorphine and increased relative bioavailability.1

Watch the BEMA technology video below to learn how this innovation helps you make a difference for your patients with opioid dependence.

Less total buprenorphine, same amount delivered1

Bioequivalent plasma concentration: Half the total dose of buprenorphine achieves the same plasma level as Suboxone tablets.

This graph illustrates that the exposure to buprenorphine from BUNAVAIL 4.2/0.7 mg and Suboxone sublingual tablet 8/2mg is bioequivalent. The y-axis of the graph measures mean concentration of buprenorphine in 0.5 ng/mL increments from 0 to 3.5 ng/mL over the x-axis of time in 2-hour increments from 0 to 24 for both BUNAVAIL and Suboxone. The concentration of buprenorphine from both BUNAVAIL and Suboxone rises in the first 2 hours and then begins to taper off over the next 22 hours.

Twice the bioavailability of Suboxone tablets: Unidirectional flow of buprenorphine helps patients efficiently absorb medication.

This infographic illustrates 2 patients: the first receives 4.2 mg of BUNAVAIL and the second patient receives 8 mg of Suboxone. Both patients absorb 2 mg of buprenorphine into the bloodstream. The BUNAVAIL patient loses 2 mg into the digestive system due to nonabsorption while the Suboxone patient loses 6 mg. Arrows illustrate the flow of medicine and how it splits between the amount swallowed vs the amount absorbed by the bloodstream.

An extra layer makes a difference1

BUNAVAIL buccal film is a small yellow square with rounded corners. It is comprised of 2 sides. This image highlights the 2 sides—the mucoadhesive and the backing layers—of the film. Arrows illustrate the unidirectional flow of the medicine.

Backing layer1

  • Creates a barrier, directing buprenorphine through the buccal mucosa
  • Reduces buprenorphine flowing back into the mouth where it might be swallowed
  • Efficient delivery of buprenorphine results in 2X bioavailability of Suboxone tablets

Mucoadhesive layer1

  • Contains buprenorphine dose
  • Adheres to inside of cheek on contact
Suboxone film

Suboxone film1

  • Buprenorphine flows undirected in mouth


  1. Vasisht N, Stark J, Bai SA, Finn A. Buprenorphine/naloxone buccal film has a relative buprenorphine bioavailability twice that of buprenorphine/naloxone tablet. Poster presented at: 45th Annual Society of Addiction Medicine (ASAM); April 10-13, 2014; Orlando, FL.



BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) is a prescription medicine indicated for the maintenance treatment of opioid dependence. BUNAVAIL should be used as part of a complete treatment plan to include counseling and psychosocial support.

Prescription use of this product is limited under the Drug Addiction Treatment Act (DATA).


Keep BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) out of the sight and reach of children. Ingestion of BUNAVAIL by a child may cause severe breathing problems and death. If a child takes BUNAVAIL, get emergency help right away.

Do not take BUNAVAIL if you are allergic to buprenorphine or naloxone, as serious negative effects including anaphylactic shock, have been reported.

Do not take BUNAVAIL before the effects of other opioids (e.g., heroin, methadone, oxycodone, morphine) have lessened as you may experience withdrawal symptoms.

Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how BUNAVAIL affects you.

BUNAVAIL contains buprenorphine, an opioid that can cause physical dependence. Your doctor can tell you more about the difference between physical dependence and drug addiction. Do not stop taking BUNAVAIL without talking to your doctor. You could become sick with uncomfortable withdrawal symptoms because your body has become used to this medicine.

Do not switch from BUNAVAIL to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of BUNAVAIL is not the same as the amount of buprenorphine in other medicines. Your doctor will prescribe a dose of BUNAVAIL that may be different than other buprenorphine-containing medicines you may have been taking.

BUNAVAIL can cause serious life-threatening breathing problems, overdose and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines, sedatives, tranquilizers or alcohol. You should not drink alcohol while taking BUNAVAIL, as this can lead to loss of consciousness or even death.

Like other opioids (e.g., heroin, methadone, oxycodone, morphine), BUNAVAIL may produce orthostatic hypotension ('dizzy spells') in ambulatory individuals.

Common side effects of BUNAVAIL include headache, drug withdrawal syndrome, lethargy (lack of energy), sweating, constipation, decrease in sleep (insomnia), fatigue and sleepiness.

Because BUNAVAIL contains naloxone, injecting BUNAVAIL may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.

BUNAVAIL can be abused in a manner similar to other opioids, legal or illicit. Keep BUNAVAIL in a safe place. Do not give your BUNAVAIL to other people, it can cause them harm or even death. Selling or giving away this medicine is against the law.

BUNAVAIL is not recommended in patients with severe hepatic impairment. BUNAVAIL may be used with caution for maintenance treatment in patients with moderate hepatic impairment.

Before taking BUNAVAIL, tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking BUNAVAIL, tell your doctor immediately as there may be significant risks to you and your baby; your baby may have symptoms of withdrawal at birth.

Before taking BUNAVAIL, talk to your doctor if you are breast-feeding or plan to breast-feed your baby. BUNAVAIL can pass into your breast milk and may harm your baby. Monitor your baby for increased sleepiness and breathing problems. Your doctor should tell you about the best way to feed your baby if you are taking BUNAVAIL.

This is not a complete list of potential adverse events associated with BUNAVAIL buccal film. Please see full Prescribing Information for a complete list.

To report negative side effects associated with taking BUNAVAIL buccal film, please call 1-800-469-0261. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

For more information, please see full Prescribing Information and Medication Guide for BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII).



BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) is a prescription medicine indicated for the maintenance treatment of opioid dependence. BUNAVAIL should be used as part of a complete treatment plan to include counseling and psychosocial support.